Objective: Allergic bronchopulmonary aspergillosis (ABPA) is a fungal infection commonly seen in patients with uncontrolled severe asthma. Standard treatment includes glucocorticoids and itraconazole; however, the use of biological agents such as omalizumab and mepolizumab has shown promise in patients unresponsive to conventional therapy. This study aims to share the clinical characteristics of ABPA patients who were uncontrolled with glucocorticoids and itraconazole and subsequently treated with mepolizumab or omalizumab.
No takes yet. Share an insight, caveat, or question.
Katran et al. (2023) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: